ID   SYYM_HUMAN              Reviewed;         477 AA.
AC   Q9Y2Z4; D3DUW8; Q9H817;
DT   19-JUL-2004, integrated into UniProtKB/Swiss-Prot.
DT   19-JUL-2004, sequence version 2.
DT   10-MAY-2017, entry version 145.
DE   RecName: Full=Tyrosine--tRNA ligase, mitochondrial;
DE            EC=6.1.1.1;
DE   AltName: Full=Tyrosyl-tRNA synthetase;
DE            Short=TyrRS;
DE   Flags: Precursor;
GN   Name=YARS2; ORFNames=CGI-04;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT VAL-191.
RX   PubMed=10810093; DOI=10.1101/gr.10.5.703;
RA   Lai C.-H., Chou C.-Y., Ch'ang L.-Y., Liu C.-S., Lin W.-C.;
RT   "Identification of novel human genes evolutionarily conserved in
RT   Caenorhabditis elegans by comparative proteomics.";
RL   Genome Res. 10:703-713(2000).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16541075; DOI=10.1038/nature04569;
RA   Scherer S.E., Muzny D.M., Buhay C.J., Chen R., Cree A., Ding Y.,
RA   Dugan-Rocha S., Gill R., Gunaratne P., Harris R.A., Hawes A.C.,
RA   Hernandez J., Hodgson A.V., Hume J., Jackson A., Khan Z.M.,
RA   Kovar-Smith C., Lewis L.R., Lozado R.J., Metzker M.L.,
RA   Milosavljevic A., Miner G.R., Montgomery K.T., Morgan M.B.,
RA   Nazareth L.V., Scott G., Sodergren E., Song X.-Z., Steffen D.,
RA   Lovering R.C., Wheeler D.A., Worley K.C., Yuan Y., Zhang Z.,
RA   Adams C.Q., Ansari-Lari M.A., Ayele M., Brown M.J., Chen G., Chen Z.,
RA   Clerc-Blankenburg K.P., Davis C., Delgado O., Dinh H.H., Draper H.,
RA   Gonzalez-Garay M.L., Havlak P., Jackson L.R., Jacob L.S., Kelly S.H.,
RA   Li L., Li Z., Liu J., Liu W., Lu J., Maheshwari M., Nguyen B.-V.,
RA   Okwuonu G.O., Pasternak S., Perez L.M., Plopper F.J.H., Santibanez J.,
RA   Shen H., Tabor P.E., Verduzco D., Waldron L., Wang Q., Williams G.A.,
RA   Zhang J., Zhou J., Allen C.C., Amin A.G., Anyalebechi V., Bailey M.,
RA   Barbaria J.A., Bimage K.E., Bryant N.P., Burch P.E., Burkett C.E.,
RA   Burrell K.L., Calderon E., Cardenas V., Carter K., Casias K.,
RA   Cavazos I., Cavazos S.R., Ceasar H., Chacko J., Chan S.N., Chavez D.,
RA   Christopoulos C., Chu J., Cockrell R., Cox C.D., Dang M.,
RA   Dathorne S.R., David R., Davis C.M., Davy-Carroll L., Deshazo D.R.,
RA   Donlin J.E., D'Souza L., Eaves K.A., Egan A., Emery-Cohen A.J.,
RA   Escotto M., Flagg N., Forbes L.D., Gabisi A.M., Garza M., Hamilton C.,
RA   Henderson N., Hernandez O., Hines S., Hogues M.E., Huang M.,
RA   Idlebird D.G., Johnson R., Jolivet A., Jones S., Kagan R., King L.M.,
RA   Leal B., Lebow H., Lee S., LeVan J.M., Lewis L.C., London P.,
RA   Lorensuhewa L.M., Loulseged H., Lovett D.A., Lucier A., Lucier R.L.,
RA   Ma J., Madu R.C., Mapua P., Martindale A.D., Martinez E., Massey E.,
RA   Mawhiney S., Meador M.G., Mendez S., Mercado C., Mercado I.C.,
RA   Merritt C.E., Miner Z.L., Minja E., Mitchell T., Mohabbat F.,
RA   Mohabbat K., Montgomery B., Moore N., Morris S., Munidasa M.,
RA   Ngo R.N., Nguyen N.B., Nickerson E., Nwaokelemeh O.O., Nwokenkwo S.,
RA   Obregon M., Oguh M., Oragunye N., Oviedo R.J., Parish B.J.,
RA   Parker D.N., Parrish J., Parks K.L., Paul H.A., Payton B.A., Perez A.,
RA   Perrin W., Pickens A., Primus E.L., Pu L.-L., Puazo M., Quiles M.M.,
RA   Quiroz J.B., Rabata D., Reeves K., Ruiz S.J., Shao H., Sisson I.,
RA   Sonaike T., Sorelle R.P., Sutton A.E., Svatek A.F., Svetz L.A.,
RA   Tamerisa K.S., Taylor T.R., Teague B., Thomas N., Thorn R.D.,
RA   Trejos Z.Y., Trevino B.K., Ukegbu O.N., Urban J.B., Vasquez L.I.,
RA   Vera V.A., Villasana D.M., Wang L., Ward-Moore S., Warren J.T.,
RA   Wei X., White F., Williamson A.L., Wleczyk R., Wooden H.S.,
RA   Wooden S.H., Yen J., Yoon L., Yoon V., Zorrilla S.E., Nelson D.,
RA   Kucherlapati R., Weinstock G., Gibbs R.A.;
RT   "The finished DNA sequence of human chromosome 12.";
RL   Nature 440:346-351(2006).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Eye;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   FUNCTION, SUBCELLULAR LOCATION, AND SUBUNIT.
RX   PubMed=15779907; DOI=10.1021/bi047527z;
RA   Bonnefond L., Fender A., Rudinger-Thirion J., Giege R., Florentz C.,
RA   Sissler M.;
RT   "Toward the full set of human mitochondrial aminoacyl-tRNA
RT   synthetases: characterization of AspRS and TyrRS.";
RL   Biochemistry 44:4805-4816(2005).
RN   [7]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-355, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [8]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [9]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M.,
RA   Ayoub D., Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [10]
RP   VARIANT MLASA2 LEU-52, AND CHARACTERIZATION OF VARIANT MLASA2 LEU-52.
RX   PubMed=20598274; DOI=10.1016/j.ajhg.2010.06.001;
RA   Riley L.G., Cooper S., Hickey P., Rudinger-Thirion J., McKenzie M.,
RA   Compton A., Lim S.C., Thorburn D., Ryan M.T., Giege R., Bahlo M.,
RA   Christodoulou J.;
RT   "Mutation of the mitochondrial tyrosyl-tRNA synthetase gene, YARS2,
RT   causes myopathy, lactic acidosis, and sideroblastic anemia--MLASA
RT   syndrome.";
RL   Am. J. Hum. Genet. 87:52-59(2010).
RN   [11]
RP   VARIANT MLASA2 ASP-46.
RX   PubMed=22504945; DOI=10.1002/humu.22098;
RA   Sasarman F., Nishimura T., Thiffault I., Shoubridge E.A.;
RT   "A novel mutation in YARS2 causes myopathy with lactic acidosis and
RT   sideroblastic anemia.";
RL   Hum. Mutat. 33:1201-1206(2012).
CC   -!- FUNCTION: Catalyzes the attachment of tyrosine to tRNA(Tyr) in a
CC       two-step reaction: tyrosine is first activated by ATP to form Tyr-
CC       AMP and then transferred to the acceptor end of tRNA(Tyr).
CC       {ECO:0000269|PubMed:15779907}.
CC   -!- CATALYTIC ACTIVITY: ATP + L-tyrosine + tRNA(Tyr) = AMP +
CC       diphosphate + L-tyrosyl-tRNA(Tyr).
CC   -!- SUBUNIT: Homodimer. {ECO:0000269|PubMed:15779907}.
CC   -!- INTERACTION:
CC       Q8IZU0:FAM9B; NbExp=3; IntAct=EBI-1049286, EBI-10175124;
CC   -!- SUBCELLULAR LOCATION: Mitochondrion matrix
CC       {ECO:0000269|PubMed:15779907}.
CC   -!- DISEASE: Myopathy with lactic acidosis and sideroblastic anemia 2
CC       (MLASA2) [MIM:613561]: A rare oxidative phosphorylation disorder
CC       specific to skeletal muscle and bone marrow. Affected individuals
CC       manifest sideroblastic anemia, progressive lethargy, muscle
CC       weakness, and exercise intolerance associated with persistent
CC       lactic acidemia. {ECO:0000269|PubMed:20598274,
CC       ECO:0000269|PubMed:22504945}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the class-I aminoacyl-tRNA synthetase
CC       family. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF132939; AAD27714.1; -; mRNA.
DR   EMBL; AK024057; BAB14806.1; -; mRNA.
DR   EMBL; AC087588; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471116; EAW88517.1; -; Genomic_DNA.
DR   EMBL; CH471116; EAW88518.1; -; Genomic_DNA.
DR   EMBL; BC015625; AAH15625.1; -; mRNA.
DR   CCDS; CCDS31770.1; -.
DR   RefSeq; NP_001035526.1; NM_001040436.2.
DR   UniGene; Hs.505231; -.
DR   UniGene; Hs.706015; -.
DR   PDB; 2PID; X-ray; 2.20 A; A/B=32-375.
DR   PDB; 3ZXI; X-ray; 2.75 A; A/B=32-375.
DR   PDBsum; 2PID; -.
DR   PDBsum; 3ZXI; -.
DR   ProteinModelPortal; Q9Y2Z4; -.
DR   SMR; Q9Y2Z4; -.
DR   BioGrid; 119258; 43.
DR   DIP; DIP-29487N; -.
DR   IntAct; Q9Y2Z4; 13.
DR   MINT; MINT-4832075; -.
DR   STRING; 9606.ENSP00000320658; -.
DR   DrugBank; DB00135; L-Tyrosine.
DR   iPTMnet; Q9Y2Z4; -.
DR   PhosphoSitePlus; Q9Y2Z4; -.
DR   SwissPalm; Q9Y2Z4; -.
DR   BioMuta; YARS2; -.
DR   DMDM; 50401709; -.
DR   EPD; Q9Y2Z4; -.
DR   MaxQB; Q9Y2Z4; -.
DR   PaxDb; Q9Y2Z4; -.
DR   PeptideAtlas; Q9Y2Z4; -.
DR   PRIDE; Q9Y2Z4; -.
DR   DNASU; 51067; -.
DR   Ensembl; ENST00000324868; ENSP00000320658; ENSG00000139131.
DR   GeneID; 51067; -.
DR   KEGG; hsa:51067; -.
DR   UCSC; uc001rli.4; human.
DR   CTD; 51067; -.
DR   DisGeNET; 51067; -.
DR   GeneCards; YARS2; -.
DR   HGNC; HGNC:24249; YARS2.
DR   HPA; HPA038721; -.
DR   HPA; HPA057610; -.
DR   HPA; HPA074097; -.
DR   MalaCards; YARS2; -.
DR   MIM; 610957; gene.
DR   MIM; 613561; phenotype.
DR   neXtProt; NX_Q9Y2Z4; -.
DR   OpenTargets; ENSG00000139131; -.
DR   Orphanet; 2598; Mitochondrial myopathy and sideroblastic anemia.
DR   PharmGKB; PA142670559; -.
DR   eggNOG; KOG2623; Eukaryota.
DR   eggNOG; COG0162; LUCA.
DR   GeneTree; ENSGT00390000013709; -.
DR   HOGENOM; HOG000242790; -.
DR   HOVERGEN; HBG056052; -.
DR   InParanoid; Q9Y2Z4; -.
DR   KO; K01866; -.
DR   OMA; EFFLDPG; -.
DR   OrthoDB; EOG091G06NG; -.
DR   PhylomeDB; Q9Y2Z4; -.
DR   TreeFam; TF105974; -.
DR   BRENDA; 6.1.1.1; 2681.
DR   Reactome; R-HSA-379726; Mitochondrial tRNA aminoacylation.
DR   ChiTaRS; YARS2; human.
DR   EvolutionaryTrace; Q9Y2Z4; -.
DR   GenomeRNAi; 51067; -.
DR   PRO; PR:Q9Y2Z4; -.
DR   Proteomes; UP000005640; Chromosome 12.
DR   Bgee; ENSG00000139131; -.
DR   CleanEx; HS_YARS2; -.
DR   ExpressionAtlas; Q9Y2Z4; baseline and differential.
DR   Genevisible; Q9Y2Z4; HS.
DR   GO; GO:0005829; C:cytosol; IBA:GO_Central.
DR   GO; GO:0005759; C:mitochondrial matrix; TAS:Reactome.
DR   GO; GO:0005739; C:mitochondrion; IDA:HPA.
DR   GO; GO:0016604; C:nuclear body; IDA:HPA.
DR   GO; GO:0005524; F:ATP binding; TAS:BHF-UCL.
DR   GO; GO:0042803; F:protein homodimerization activity; IPI:BHF-UCL.
DR   GO; GO:0003723; F:RNA binding; IDA:UniProtKB.
DR   GO; GO:0000049; F:tRNA binding; IDA:BHF-UCL.
DR   GO; GO:0072545; F:tyrosine binding; IDA:BHF-UCL.
DR   GO; GO:0004831; F:tyrosine-tRNA ligase activity; IDA:BHF-UCL.
DR   GO; GO:0070184; P:mitochondrial tyrosyl-tRNA aminoacylation; IMP:BHF-UCL.
DR   GO; GO:0006412; P:translation; NAS:UniProtKB.
DR   GO; GO:0043039; P:tRNA aminoacylation; IDA:BHF-UCL.
DR   GO; GO:0006418; P:tRNA aminoacylation for protein translation; TAS:Reactome.
DR   CDD; cd00805; TyrRS_core; 1.
DR   Gene3D; 3.10.290.10; -; 1.
DR   Gene3D; 3.40.50.620; -; 1.
DR   InterPro; IPR001412; aa-tRNA-synth_I_CS.
DR   InterPro; IPR002305; aa-tRNA-synth_Ic.
DR   InterPro; IPR014729; Rossmann-like_a/b/a_fold.
DR   InterPro; IPR002942; S4_RNA-bd.
DR   InterPro; IPR002307; Tyr-tRNA-ligase.
DR   InterPro; IPR024088; Tyr-tRNA-ligase_bac-type.
DR   PANTHER; PTHR11766; PTHR11766; 1.
DR   Pfam; PF00579; tRNA-synt_1b; 1.
DR   PRINTS; PR01040; TRNASYNTHTYR.
DR   TIGRFAMs; TIGR00234; tyrS; 1.
DR   PROSITE; PS00178; AA_TRNA_LIGASE_I; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Aminoacyl-tRNA synthetase; ATP-binding;
KW   Complete proteome; Disease mutation; Ligase; Mitochondrion;
KW   Nucleotide-binding; Polymorphism; Protein biosynthesis;
KW   Reference proteome; Transit peptide.
FT   TRANSIT       1     16       Mitochondrion. {ECO:0000255}.
FT   CHAIN        17    477       Tyrosine--tRNA ligase, mitochondrial.
FT                                /FTId=PRO_0000035830.
FT   MOTIF        82     91       "HIGH" region. {ECO:0000305}.
FT   MOTIF       281    285       "KMSKS" region. {ECO:0000305}.
FT   BINDING      77     77       Tyrosine. {ECO:0000250|UniProtKB:P54577}.
FT   BINDING     221    221       Tyrosine. {ECO:0000250|UniProtKB:P54577}.
FT   BINDING     225    225       Tyrosine. {ECO:0000250|UniProtKB:P54577}.
FT   BINDING     228    228       Tyrosine. {ECO:0000250|UniProtKB:P54577}.
FT   BINDING     247    247       Tyrosine. {ECO:0000250|UniProtKB:P54577}.
FT   BINDING     284    284       ATP. {ECO:0000250}.
FT   MOD_RES     355    355       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES     367    367       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:Q8BYL4}.
FT   VARIANT      46     46       G -> D (in MLASA2; dbSNP:rs587777213).
FT                                {ECO:0000269|PubMed:22504945}.
FT                                /FTId=VAR_068646.
FT   VARIANT      52     52       F -> L (in MLASA2; has a 2-fold reduction
FT                                in catalytic activity and a reduction in
FT                                affinity for tRNA-tyr resulting in an
FT                                overall 9-fold loss of catalytic
FT                                efficiency; dbSNP:rs267607180).
FT                                {ECO:0000269|PubMed:20598274}.
FT                                /FTId=VAR_064188.
FT   VARIANT     191    191       G -> V (in dbSNP:rs11539445).
FT                                {ECO:0000269|PubMed:10810093}.
FT                                /FTId=VAR_034534.
FT   CONFLICT      1      4       MAAP -> MGA (in Ref. 1; AAD27714).
FT                                {ECO:0000305}.
FT   CONFLICT    118    118       R -> A (in Ref. 1; AAD27714).
FT                                {ECO:0000305}.
FT   CONFLICT    272    272       P -> T (in Ref. 1; AAD27714).
FT                                {ECO:0000305}.
FT   CONFLICT    311    311       D -> E (in Ref. 1; AAD27714).
FT                                {ECO:0000305}.
FT   HELIX        38     45       {ECO:0000244|PDB:2PID}.
FT   STRAND       50     52       {ECO:0000244|PDB:2PID}.
FT   HELIX        61     64       {ECO:0000244|PDB:2PID}.
FT   STRAND       67     70       {ECO:0000244|PDB:2PID}.
FT   STRAND       75     80       {ECO:0000244|PDB:2PID}.
FT   STRAND       83     86       {ECO:0000244|PDB:2PID}.
FT   HELIX        89    103       {ECO:0000244|PDB:2PID}.
FT   STRAND      107    112       {ECO:0000244|PDB:2PID}.
FT   HELIX       116    118       {ECO:0000244|PDB:2PID}.
FT   HELIX       134    158       {ECO:0000244|PDB:2PID}.
FT   STRAND      168    172       {ECO:0000244|PDB:2PID}.
FT   HELIX       174    177       {ECO:0000244|PDB:2PID}.
FT   HELIX       182    189       {ECO:0000244|PDB:2PID}.
FT   HELIX       190    192       {ECO:0000244|PDB:2PID}.
FT   HELIX       195    200       {ECO:0000244|PDB:2PID}.
FT   HELIX       202    208       {ECO:0000244|PDB:2PID}.
FT   STRAND      210    212       {ECO:0000244|PDB:3ZXI}.
FT   HELIX       216    236       {ECO:0000244|PDB:2PID}.
FT   STRAND      240    244       {ECO:0000244|PDB:2PID}.
FT   HELIX       245    247       {ECO:0000244|PDB:2PID}.
FT   HELIX       248    261       {ECO:0000244|PDB:2PID}.
FT   STRAND      267    271       {ECO:0000244|PDB:2PID}.
FT   STRAND      291    293       {ECO:0000244|PDB:2PID}.
FT   TURN        294    296       {ECO:0000244|PDB:2PID}.
FT   HELIX       299    307       {ECO:0000244|PDB:2PID}.
FT   HELIX       311    321       {ECO:0000244|PDB:2PID}.
FT   HELIX       326    338       {ECO:0000244|PDB:2PID}.
FT   HELIX       340    342       {ECO:0000244|PDB:2PID}.
FT   HELIX       344    372       {ECO:0000244|PDB:2PID}.
SQ   SEQUENCE   477 AA;  53199 MW;  C513B8FE1E7A09E4 CRC64;
     MAAPILRSFS WGRWSGTLNL SVLLPLGLRK AHSGAQGLLA AQKARGLFKD FFPETGTKIE
     LPELFDRGTA SFPQTIYCGF DPTADSLHVG HLLALLGLFH LQRAGHNVIA LVGGATARLG
     DPSGRTKERE ALETERVRAN ARALRLGLEA LAANHQQLFT DGRSWGSFTV LDNSAWYQKQ
     HLVDFLAAVG GHFRMGTLLS RQSVQLRLKS PEGMSLAEFF YQVLQAYDFY YLFQRYGCRV
     QLGGSDQLGN IMSGYEFINK LTGEDVFGIT VPLITSTTGA KLGKSAGNAV WLNRDKTSPF
     ELYQFFVRQP DDSVERYLKL FTFLPLPEID HIMQLHVKEP ERRGPQKRLA AEVTKLVHGR
     EGLDSAKRCT QALYHSSIDA LEVMSDQELK ELFKEAPFSE FFLDPGTSVL DTCRKANAIP
     DGPRGYRMIT EGGVSINHQQ VTNPESVLIV GQHILKNGLS LLKIGKRNFY IIKWLQL
//
